STOCK TITAN

Icon Plc - ICLR STOCK NEWS

Welcome to our dedicated page for Icon Plc news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on Icon Plc stock.

ICON plc (ICLR) is a leading global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Ireland, ICON specializes in the strategic development, management, and analysis of clinical programs that support clinical development from compound selection to phase I-IV clinical studies.

Operating in a highly fragmented industry, ICON is among a select group of organizations with the capability and expertise to conduct clinical trials and development projects on both a local and global scale. The company's core services are versatile, offering both standalone and integrated full-service solutions to meet diverse client needs. This operational flexibility ensures that ICON can tailor its services to individual project requirements.

ICON's array of services includes end-to-end pharmacovigilance, which covers post-marketing surveillance activities. The company also provides ancillary services, such as laboratory and imaging capabilities, enhancing its comprehensive approach to drug development and clinical research.

This robust service offering positions ICON as a pivotal partner for firms aiming to bring their medical innovations to market. Recent achievements and ongoing projects underscore ICON's commitment to excellence and innovation in clinical research. The company's financial health remains strong, supported by strategic partnerships and a global client base.

Stay updated on ICON plc's latest developments, performance updates, and industry news to understand the significant role this organization plays in advancing healthcare solutions worldwide.

Rhea-AI Summary

ICON plc (NASDAQ: ICLR) announced that CEO Dr. Steve Cutler will present at the 40th Annual JP Morgan Healthcare Conference on January 12, 2022, at 07:30 AM ET. This conference is a significant event in the healthcare sector where industry leaders share insights. ICON, headquartered in Dublin, Ireland, employs approximately 37,960 staff globally and focuses on advancing clinical research. The company provides outsourced services to various organizations, emphasizing innovations in drug development and patient care. For updates and live webcasts, visit the Investor section on ICON's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
-
Rhea-AI Summary

ICON plc (NASDAQ:ICLR) has released its 2020 Environmental, Social and Governance (ESG) Report, following its acquisition of PRA Health Sciences. The report outlines ESG advancements made by both organizations and details commitments and policies for the unified company. CEO Steve Cutler emphasized the focus on enhancing ESG strategies to make a positive impact. The complete report is accessible for review on ICON's official website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
none
Rhea-AI Summary

ICON plc (NASDAQ: ICLR) announced the expansion of its Accellacare Site Network with new partnerships, enhancing its reach in four countries: the U.S., Germany, Spain, and Poland. This growth brings the total active locations to 112 across eight countries, including new sites in Florida and California. The expansion aims to increase patient access and improve clinical trial recruiting, accessing over 9 million patients. This move supports quicker drug development timelines and costs for clients, particularly in central nervous system and immune-inflammation therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
-
Rhea-AI Summary

ICON plc (NASDAQ: ICLR) has announced participation in two upcoming conferences. CFO Brendan Brennan will present at the 30th Annual Credit Suisse Healthcare Conference on November 9, 2021, at 8:50 AM ET, and at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 12:10 PM ET. Investors can find updates and links to live webcasts on the company's Investor Relations website. With approximately 37,960 employees across 159 locations worldwide, ICON focuses on advancing clinical research and improving patient lives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
conferences
-
News
Rhea-AI Summary

ICON plc (NASDAQ: ICLR) reported impressive Q3 2021 results with record net business wins of $2,374 million and a net book to bill ratio of 1.27. Adjusted revenue reached $1,870.4 million, marking a 167% year-on-year increase. Adjusted net income was $209.8 million, or $2.55 per diluted share. However, GAAP net loss reached $94.3 million. The company revised its full-year revenue guidance to $5,430 - $5,530 million, a 94% - 98% increase year-on-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
Rhea-AI Summary

ICON plc has received a €4 million funding grant from Enterprise Ireland, aimed at enhancing its digital health technology and data analytics solutions. This R&D support will facilitate the development of decentralized clinical trial technology, providing participants with options for virtual visits and mobile reporting. This strategic investment aims to improve clinical trial efficiency and participation, reduce costs, and ensure real-time data access. The funding highlights ICON's commitment to advancing clinical research and delivering better patient outcomes globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
-
Rhea-AI Summary

ICON plc (NASDAQ: ICLR) announced that CFO Brendan Brennan will present at two upcoming healthcare conferences. He will speak at the Wells Fargo 16th Annual Healthcare Conference on September 9, 2021, at 8:00 AM ET, and at the Baird Global Healthcare Conference on September 15, 2021, at 8:30 AM ET.

Investors can find updates on these events and links to live webcasts on the Investor section of ICON's website. As of June 30, 2021, ICON employed approximately 16,480 employees across 89 locations worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
-
Rhea-AI Summary

ICON plc (NASDAQ: ICLR) reported a strong Q2 2021, showcasing a record net business win of $1,106 million and a remarkable revenue increase of 40.5% year-over-year to $871 million. Adjusted EPS surged by 76.8% to $2.12. The acquisition of PRA is poised to enhance growth and shareholder value, with updated revenue guidance for 2021 between $5,300 million and $5,500 million. Cash generated from operations was $128.4 million, while net cash reached $707.2 million. Overall, the results highlight a robust financial position and positive outlook for the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
Rhea-AI Summary

ICON plc (NASDAQ: ICLR) successfully held its Annual General Meeting (AGM) on July 20, 2021, where all recommended resolutions were passed by shareholders. Key resolutions included re-election of directors, approval of financial reports, and authorizations for share allotment and market purchases. Approximately 45.4 million votes were cast. Notable outcomes were re-elections of Ciaran Murray, Joan Garahy, and Eugene McCague, alongside approvals for the fixing of auditors’ remuneration and disapplication of pre-emption rights. The company continues to emphasize growth and innovation in clinical research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none

FAQ

What is the current stock price of Icon Plc (ICLR)?

The current stock price of Icon Plc (ICLR) is $207.51 as of December 20, 2024.

What is the market cap of Icon Plc (ICLR)?

The market cap of Icon Plc (ICLR) is approximately 16.9B.

What services does ICON plc provide?

ICON plc provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries, including clinical trial management, laboratory, and imaging capabilities.

Where is ICON plc headquartered?

ICON plc is headquartered in Ireland.

What is ICON's role in pharmaceutical development?

ICON specializes in the strategic development, management, and analysis of clinical programs, supporting clinical development from compound selection to phase I-IV clinical studies.

Does ICON offer standalone and integrated services?

Yes, ICON provides both standalone and integrated full-service solutions to meet diverse client needs.

What is pharmacovigilance, and does ICON provide it?

Pharmacovigilance involves monitoring the effects of drugs after they have been licensed for use to ensure they are safe. ICON offers end-to-end pharmacovigilance services, including post-marketing surveillance.

What industries does ICON serve?

ICON serves the pharmaceutical, biotechnology, and medical device industries.

What makes ICON a leader in its industry?

ICON's capability to conduct clinical trials globally, strong financial health, strategic partnerships, and comprehensive service offerings make it a leader in the industry.

How can I stay updated on ICON's latest news and developments?

You can stay updated on ICON's latest news and developments by visiting reputable stock market websites or ICON's official website.

What are some of ICON's ancillary services?

ICON offers ancillary services, including laboratory and imaging capabilities, to support drug development and clinical research.

What type of clients does ICON work with?

ICON works with clients in the pharmaceutical, biotechnology, and medical device industries, providing them with comprehensive development and clinical trial services.

Icon Plc

Nasdaq:ICLR

ICLR Rankings

ICLR Stock Data

16.93B
81.85M
0.66%
101.13%
1.55%
Diagnostics & Research
Healthcare
Link
United States of America
Dublin